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Abstract The protein-tyrosine phosphatase inhibitors pervana-
date, permolybdate, H2O2, and to a much lesser extent vanadate, 
increased the amount of cellular phosphotyrosine and induced 
tyrosine phosphorylation of connexin43 (Cx43) in early passage 
hamster embryo fibroblasts. The presence of phosphotyrosine in 
Cx43 immunoprecipitates from pervanadate-treated cells was 
shown by a phosphotyrosine-specific antibody and a phosphotyr-
osine-specific phosphatase. Pervanadate-induced Cx43 tyrosine 
phosphorylation was further verified by phosphoamino acid 
analysis, while no phosphotyrosine was present in control cells. 
This is the first observation of tyrosine phosphorylation of 
connexins in normal cells. 
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1. Introduction 
Gap junctional intercellular communication (GJIC) is as-
sumed to be involved in several fundamental processes like 
development, differentiation and growth control [1,2], and 
many signal transduction pathways are known to affect 
GJIC [3]. Gap junction channel proteins are called connexins. 
At present, 13 connexin genes have been cloned from mam-
mals. Connexin43 (Cx43) is a major connexin present in many 
tissues [4]. Most connexins appear to be phosphoproteins or 
to possess potential phosphorylation sites. Connexins may be 
targets for several serine/threonine kinases [5-7]. The phos-
phorylation of Cx43 occurs almost exclusively on serine. 
There are conflicting results whether there is a rapid turnover 
of phosphates in Cx43 [8] or not [9]. No phosphatase has been 
identified as responsible for dephosphorylation of connexins 
in intact cells, but relatively little work has been devoted to 
the question. Okadaic acid and similar compounds do not 
affect GJIC or the phosphorylation status of Cx43 in Syrian 
hamster embryo (SHE) cells, even after treatment with 12-0-
tetradecanoylphorbol 13-acetate [10]. However, okadaic acid 
delays the normalization of Cx43 band pattern in rat liver 
epithelial cells treated with epidermal growth factor [11]. Va-
nadate is a classical protein-tyrosine phosphatase (PTPase) 
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inhibitor. Usually, it has little effect on GJIC [10,12,13], but it 
affects GJIC in cells transfected with a temperature-sensitive 
variant of v-Src [14]. H2O2 is an oxidative agent and a PTPase 
inhibitor [15,16]. It may slightly inhibit GJIC in some cell 
types [17,18], but is without effect [19] or may even increase 
GJIC in other cells [20]. However, pervanadate (a mixture of 
vanadate and H 20 2) significantly and potently affects GJIC 
and the phosphorylation status of Cx43 [10]. 
Pervanadate is a PTPase inhibitor [15,21] with specificity 
differing from vanadate [21]. The biological effect of pervana-
date was first detected by its insulin mimesis [22], but it also 
affects a number of other cellular and biochemical functions, 
such as T-cell activation-like events [23-25], tyrosine phos-
phorylation and activation of phospholipases Cy [24,26] and 
D [27], increased formation of inositol phosphates [26,28], and 
activation of the transcription factor N F - K B [24]. 
We have recently characterized the nature of pervanadate 
[29]. The results indicated that the biologically active com-
pound of pervanadate is diperoxovanadate(V) (see [29] for 
further references). Also permolybdate is an insulin mimetic 
[30], it decreases GJIC and alters the Cx43 band pattern in 
Western blots [31]. Permolybdate is probably diperoxomolyb-
date [31]. The strong effect of pervanadate and permolybdate 
on both GJIC and Cx43 phosphorylation in intact cells raised 
the possibility that these compounds induce tyrosine phos-
phorylation of Cx43. Up to now, tyrosine phosphorylation 
of connexins in intact cells has only been detected in cells 
transfected with oncogenes encoding the activated tyrosine 
kinases v-Src [8,32,33] and v-Fps [34]. 
2. Materials and methods 
2.1. Chemicals 
Na3V04 (sodium orthovanadate, vanadate) was bought from Sigma 
(St. Louis, MO, USA). H202 and Na2Mo04-2H20 (sodium molyb-
date) were obtained from Aldrich (Steinheim, Germany). 
2.2. Preparation of pervanadate and permolybdate 
The concentration of H202 was controlled by potassium perman-
ganate titration. The metal salts were dissolved in water to 1 M 
(molybdate) or 300 mM (vanadate). Pervanadate was made by co-
incubating 30 mM vanadate and 60 mM H202. Permolybdate was 
made by acidifying 100 mM molybdate with 120 mM HC1 before 
addition of 200 mM H202. The metal salts and H202 were co-incu-
bated for 15 min (room temperature, in the dark) before addition to 
the cells. The concentration of the metal ion is regarded as the con-
centration of the per-compound. 
In some experiments the alkaline colorless stock solution of vana-
date was neutralized with HC1, giving the yellow-orange 'decavana-
date' solution. 
2.3. Cell cultures 
Primary cell cultures (mainly fibroblasts) from Syrian hamster 
(Wright, Chelmsford, Essex, UK) embryos (SHE cells) were prepared 
and cultured as described [10], and used between passages 2 and 10. 
No differences in responses were found between early and late pas-
sages. 
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2.4. Western blotting and detection of phosphotyrosine in Cx43 
Western blotting was performed as described [10] applying 10-20 ug 
protein/lane. Cx43 was detected by an anti-peptide rabbit antiserum 
[10]. Phosphotyrosine was detected by a phosphotyrosine-specific 
monoclonal antibody (4G10; Upstate Biotechnology, Inc.). 
For immunoprecipitation, the cells were scraped into immunopre-
cipitation buffer (20 mM Tris pH 9.0, 0.3% (w/v) sodium lauroyl 
sarcosine, 150 mM NaCl, 1% (w/v) Triton X-100, 20 ug/ml pepstatin 
A, 20 uM leupeptin, 50 units/ml aprotinin and 1 mM phenylmethyl-
sulfonyl fluoride), sonicated, and pre-cleared with protein A Sephar-
ose CL-4B (Pharmacia, Uppsala, Sweden). Cx43 was immunoprecipi-
tated with anti-Cx43 antiserum and protein A Sepharose CL-4B. The 
immune complexes were washed 5 times before further treatment. 
Tyrosine phosphorylation of Cx43 was examined using several meth-
ods. (i) The immunoprecipitates were subjected to Western blotting, 
using 4G10 as the primary antibody, (ii) A recombinant fragment of a 
phosphotyrosine-specific phosphatase from Yersinia enterocolitica 
(Boehringer Mannheim) was employed to dephosphorylate the immu-
noprecipitates. The specific activity of the Yersinia phosphatase is at 
least 5 orders of magnitude higher with phosphotyrosine as substrate 
compared to phosphoserine or phosphothreonine [35]. Dephosphoryl-
ation was performed on half of the immunoprecipitate as described 
by the supplier. The other half was buffer treated. After solubilization 
in Laemmli sample buffer, each part was again divided into two, one 
part for blotting with the anti-Cx43 antiserum, the other part for 
blotting with 4G10. (iii) Immunoprecipitates from 32P-labeled cells 
(4 h of 1 mCi/60 mm dish followed by 30 min exposure to 30 uM 
pervanadate or vehicle) were blotted to polyvinylidene difluoride 
membranes, and the position of labeled Cx43 was identified by auto-
radiography. The appropriate areas were cut out from the blots, and 
subjected to acid hydrolysis. Two-dimensional phosphoamino acid 
analysis was done as described [36]. 
3. Results 
Cx43 from control SHE cells separated into three major 
Fig. 1. Induction of cellular tyrosine phosphorylation (upper panel) 
and alterations in band pattern of Cx43 (lower panel). SHE cells 
were vehicle-treated (control, C), or exposed to 10 mM vanadate 
(Van), 3 mM H 2 0 2 , 300 uM permolybdate (PMo) or 30 uM perva-
nadate (PV) for 30 min before sampling. Western blots were probed 
with 4G10 (upper panel) or anti-Cx43 antiserum (lower panel). For 
comparison, immunoprecipitate from control cells (IPC) is shown. 
P, prestained standards with calibrated molecular mass in kDa on 
the left. 
Fig. 2. Detection of phosphotyrosine in Cx43. Cx43 was immuno-
precipitated from control cells and cells treated with molybdate (10 
mM), vanadate (10 mM), H 2 0 2 (3 mM), permolybdate (300 u.M) or 
pervanadate (30 uM) for 30 min. Each of the immunoprecipitates 
was divided into two, and one of the halves was treated with the 
phosphotyrosine-specific phosphatase from Yersinia enterocolitica. 
Each half was again divided into two. One part was probed with 
the anti-Cx43 antiserum (lower panel). The other part was probed 
with 4G10 (upper panel). 
bands and some minor bands (Fig. 1, lower panel). The lower 
major band was the non-phosphorylated (NP) form of Cx43, 
and the upper bands were phosphorylated forms of Cx43 [10]. 
As in many other cell types, the arbitrary assignment PI and 
P2 will be used for the major lower and upper phosphorylated 
bands in unexposed cells. A minor species was found just 
above NP. There was a small amount of phosphotyrosine-
containing proteins in control cells (Fig. 1, upper panel), the 
major species were migrating in positions corresponding to 
approximately 83, 85, 91, 95, 115, 125 and 160 kDa, and 
with some minor species between 60 and 72 kDa. 
Vanadate gave a small increase in phosphotyrosine and a 
slight blurring of the Cx band pattern at 3-10 mM (Fig. 1). 
Vanadate strongly increased the pH of the medium when 
added at 3 and 10 mM, but a pH shock was not found to 
mimic the effects of vanadate (not shown). Neutralized vana-
date ('decavanadate') seemed to be slightly less potent than 
vanadate (not shown). H2O2 (3 mM) increased cellular phos-
photyrosine (Fig. 1, upper panel). The Cx43 band pattern was 
also changed at 3 mM H2O2 (Fig. 1, lower panel). This was 
characterized by a decrease in the intensity of the NP species 
of Cx43, and an increased smear in the area of the upper 
phosphorylated Cx43 bands. It should be noted that the pres-
ent batch of SHE cells was more sensitive to H2O2 than most 
other cell batches tested (by a factor of 3). Also pervanadate 
and permolybdate caused increases in cellular phosphotyro-
sine and prominent changes in the band pattern of Cx43, but 
at substantially lower concentrations than H 2 0 2 (Fig. 1, lower 
panel). Cx43 immunoprecipitates from control cells showed 
the same pattern of bands as the corresponding total homog-
enates (Fig. 1, lower panel), with the exception that P2 often 
separated into double bands. This difference was probably due 
to a highly abundant protein migrating immediately above P2 
in the total homogenates. The yield of P2 in the immunopre-
cipitates could vary somewhat (compare with Fig. 2, lower 
panel). The strong band migrating at approximately 55 kDa 
was the heavy chain of the immunoglobulins. The heavy chain 
gave a non-specific reaction in the phosphotyrosine blots (Fig. 
S.-O. Mikalsen et allFEBS Letters 401 (1997) 271-275 273 
Fig. 3. Phosphoamino acid analysis of Cx43. Cells were labeled with 
32P for 4 h before immunoprecipitation of Cx43 and Western blot-
ting. During the last 30 min, the cells were vehicle-treated or ex-
posed to 30 uM pervanadate. A: The position of labeled Cx43 was 
identified by autoradiography, and the boxed areas of the corre-
sponding blot were cut out and subjected to acid hydrolysis. C, con-
trol; PV, pervanadate. The positions of the prestained standards on 
the blot are marked on the left. The rectangular mark at the top of 
the PV lane is one of several position/identification markers for 
alignment of the blot and autoradiogram. The autoradiogram was 
exposed for 1 h. B, C: Separation of the phosphoamino acids was 
by (1) electrophoresis and (2) ascending chromatography. B: Phos-
phoamino acid analysis of Cx43 from control cells. C: Phosphoami-
no acid analysis from pervanadate-treated cells. The positions of 
phosphoamino acid standards are marked by the stippled lines (PS, 
phosphoserine; PT, phosphothreonine; PY, phosphotyrosine). The 
autoradiograms in B and C were exposed for 15 days with intensify-
ing screens at —70°C. 
1, upper panel). The immunoprecipitation of Cx43 was not 
quantitative (not shown). 
It was investigated if the compounds induced tyrosine phos-
phorylation of Cx43. Cx43 immunoprecipitates were probed 
with a combination of a phosphotyrosine-specific phosphatase 
from Yersinia enterocolitica, the anti-Cx43 antiserum (Fig. 2, 
lower panel) and a monoclonal antiphosphotyrosine antibody 
(Fig. 2, upper panel). Treatment of the immunoprecipitates 
with the Yersinia phosphatase gave no or very little change 
in the Cx43 band pattern from control cells and cells treated 
with 10 mM molybdate or 10 mM vanadate (Fig. 2, lower 
panel). Immunoprecipitates from cells exposed to H2O2 (3 
mM), permolybdate (300 uM) and pervanadate (30 uM) 
showed clear changes subsequent to the Yersinia phosphatase 
treatment. The lower non-phosphorylated Cx43 band reap-
peared strongly together with bands corresponding to the 
two major upper bands in immunoprecipitates from untreated 
cells, although the upper bands reappeared with lower inten-
sity than in the control. This could suggest a decrease in serine 
phosphorylation of Cx43. 
The antiphosphotyrosine monoclonal antibody did not re-
act against Cx43 immunoprecipitates from control cells and 
molybdate-treated cells, except for the weak non-specific reac-
tion against the immunoglobulin heavy chain (Fig. 2, upper 
panel). The antibody reacted only very weakly against immu-
noprecipitates from cells treated with vanadate (10 mM). This 
reaction was eliminated by the treatment of the immunopre-
cipitates with the phosphotyrosine-specific phosphatase (Fig. 
2, upper panel). The antiphosphotyrosine antibody reacted 
strongly against the Cx43 immunoprecipitates from cells treat-
ed with H2O2 (3 mM), permolybdate (300 |xM) or pervana-
date (30 uM) for 30 min (Fig. 2, upper panel). The region of 
antiphosphotyrosine reaction corresponded to a somewhat ex-
tended P1-P2 area, with no reaction in the NP area. The 
reactions were eliminated by the Yersinia phosphatase treat-
ment (Fig. 2, upper panel). 
Cx43 immunoprecipitates from control and pervanadate-
treated cells were subjected to phosphoamino acid analysis 
(Fig. 3). Cx43 was immunoprecipitated from 32P-labeled cells. 
The areas of the blot to use for acid hydrolysis were identified 
by autoradiography (Fig. 3A). In contrast to the relatively 
clear Cx43 P1/P2 bands obtained with horseradish peroxi-
dase/chloronaphthol staining (Figs. 1 and 2, lower panels), 
the autoradiogram (Fig. 3A) of 32P-labeled Cx43 could not 
distinguish between PI and P2. This has also been observed 
previously [37]. Only phosphoserine could be detected in Cx43 
from control cells (Fig. 3B), while both phosphoserine and 
phosphotyrosine were evident in Cx43 from pervanadate-
treated cells (Fig. 3C). Consistent with the lower intensity of 
the P1/P2 bands in Yersinia phosphatase-treated Cx43 immu-
noprecipitates described above (Fig. 2), pervanadate caused 
an apparent decrease in the content of phosphoserine in 
Cx43 relative to the control. The acid hydrolysis appeared 
to be incomplete in some of the experiments (much radioac-
tivity around the origin). We have therefore not quantified the 
decrease in phosphoserine content. 
4. Discussion 
Tyrosine phosphorylation of connexins in intact cells has 
only been found in cells transfected with the v-src [8,32,33] 
and v-fps oncogenes [34]. Both encode for activated tyrosine 
kinases. The activated epidermal growth factor receptor does 
not phosphorylate Cx43 directly [11], but rather through the 
activated mitogen-activated protein kinase [7,38]. However, 
the epidermal growth factor receptor tyrosine kinase may di-
rectly phosphorylate tyrosines in Cx32 in a cell-free system, 
but with a low efficiency [39]. We show here that pervanadate 
and permolybdate at |iM concentrations and H2O2 at mM 
concentration cause tyrosine phosphorylation of Cx43 in in-
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tact and normal cells. Per-compounds may therefore be useful 
tools to study the effects of tyrosine phosphorylation of Cx43. 
Pervanadate [29] and permolybdate [31] have prominently 
higher biological potency than their parent compounds. The 
induction of phosphotyrosine in Cx43 by the present com-
pounds can be achieved in two ways. They may exclusively 
inhibit one or more PTPases that act on Cx43, thereby dis-
closing a tyrosine kinase that has Cx43 as its normal sub-
strate. Alternatively, they may indirectly or directly activate 
a tyrosine kinase that acts on Cx43. c-Src and c-Fps could be 
potential candidates as Cx43 tyrosine kinases based on the 
Cx43 phosphorylating activities of their activated viral homo-
logues [8,32-34]. It was recently demonstrated that c-Src could 
phosphorylate tyrosines in Cx43 in a cell-free system [40]. 
Tyrosine phosphorylation of c-Src is involved in bo th positive 
and negative regulation of its activity [41]. There is no infor-
mation if or how pervanadate and permolybdate affect the 
phosphorylation status of c-Src. Potentially, per-compounds 
could contribute to the activation of c-Src indirectly by gen-
erating numerous alternative binding sites for the c-Src SH2 
domain due to the massive increase in cellular tyrosine phos-
phorylation. In support , the Src-family tyrosine kinases Fyn 
and Lck were activated by pervanadate in T-cells [23-25]. 
Members of other tyrosine kinase families [42,43] can be acti-
vated in cells by one or more of the present compounds, and 
might therefore also be considered as potential Cx43 tyrosine 
kinases. 
The present results suggest that gap junctions in non-trans-
formed cells might be targets for tyrosine kinases along with 
other types of cellular junctions and adhesion molecules [44-
47]. The normal content of phosphotyrosine in Cx43 is clearly 
below the limit of detection. This could be achieved if a very 
small subpopulation of Cx43 is transiently tyrosine phos-
phorylated. Tyrosine phosphorylation may occur on Cx43 
molecules incorporated into functional gap junctional chan-
nels, and thereby affect the open-state probability of the chan-
nels or other factors that affect their gating properties. How-
ever, since the Cx43 N P species disappears after exposure to 
the per-compounds, and it reappears after treatment of im-
munoprecipitates with a PTPase, it is clear that the treatments 
can induce tyrosine phosphorylation on the previously non-
phosphorylated Cx43 species. The Cx43 N P species may not 
be incorporated into functional gap junctional channels in the 
cell membrane [37,48]. In this case, tyrosine phosphorylation 
may not immediately affect the gap junctional intercellular 
communication, but rather the Cx43 transport kinetics or 
the assembly into connexons. We are presently studying these 
alternatives. 
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